Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics (NASDAQ: ATRA) is a leading innovator in cellular immunotherapy, developing transformative treatments for cancer and autoimmune diseases. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Access timely updates on T-cell therapy advancements, including CAR T platform developments and collaboration progress with Memorial Sloan Kettering Cancer Center. Our curated collection features press releases about product candidates in oncology and autoimmune research, financial disclosures, and manufacturing updates.
Key content includes analysis of Phase 1-3 trial outcomes, FDA communications regarding allogeneic therapies, and licensing agreements supporting ATRA's pipeline development. Bookmark this page for direct access to primary source materials and objective reporting on the company's progress in addressing unmet medical needs through innovative immunotherapies.
Rhea-AI Summary
Atara Biotherapeutics and Pierre Fabre Laboratories announced the publication of pivotal Phase 3 ALLELE study data for tab-cel, an allogeneic T-cell therapy for EBV+ PTLD patients. The study showed a 51.2% objective response rate and a 23.0 month median duration of response. The U.S. BLA submission for tab-cel is on track for Q2 2024. The study met its primary endpoint, and tab-cel was well-tolerated with no reported adverse events. These results highlight the clinical value of tab-cel and its potential to address an urgent unmet medical need for patients with limited treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.01%
Tags
-
Rhea-AI Summary
Atara Biotherapeutics, Inc. (ATRA) announces a definitive agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727 shares of its common stock at a purchase price of $0.55 per pre-funded warrant share in a registered direct offering to entities affiliated with an existing institutional investor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.28%
Tags
-
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced the closing of a partnership expansion with Pierre Fabre Laboratories for the global commercialization of tab-cel. The company's BLA for tab-cel is on track for submission in Q2 2024, following positive new data from the pivotal ALLELE study. Atara also plans to expand its next-gen allogeneic CAR-T portfolio to include autoimmune disease ATA3219. The company's strategic restructuring has extended its cash runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.28%
Tags
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to present at 42nd Annual J.P. Morgan Healthcare Conference, showcasing its T-cell immunotherapy and EBV T-cell platform for cancer and autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
-
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced the closing of an expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM). The transaction provides Pierre Fabre Laboratories with the development, manufacturing, and commercialization rights for tab-cel in the United States and all remaining markets. Atara will receive approximately USD 27 million in cash upfront and initial inventory purchase, with the potential to receive up to a total of USD 640 million and significant double-digit tiered royalties on net sales. Atara plans to submit the BLA to the U.S. FDA for tab-cel for the treatment of post-transplant lymphoproliferative disease (PTLD) in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.49%
Tags
-
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced preclinical data on ATA3431, a next-generation allogeneic CD20/CD19-dual targeted chimeric antigen receptor (CAR) EBV T-cell therapy candidate. The data supports ATA3431's advancement into clinical testing for the treatment of B-cell malignancies, with promising results compared to an autologous CAR-T benchmark. The company is excited about the potential of ATA3431 and looks forward to evaluating it in the clinic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) reported the grant of 27,000 restricted stock units to three new employees under the 2018 Inducement Plan. The units vest over four years, subject to continuous employment. This move aims to attract and retain talent, aligning employee interests with company growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.02%
Tags
-
Rhea-AI Summary
Atara Biotherapeutics, a leader in T-cell immunotherapy, announced positive data for tabelecleucel (tab-cel® or EBVALLO™) in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease involving the central nervous system. The multicohort Phase 2 EBVision trial showed a 77.8% objective response rate in 18 patients, with a favorable safety profile. The estimated one-year overall survival rate was 70.6% for all patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
-
Rhea-AI Summary
Atara Biotherapeutics, Inc. (ATRA) to participate in fireside chat at Evercore ISI HealthCONx Conference. Pascal Touchon, President and CEO, to present at 6th Annual Evercore ISI HealthCONx Conference on November 28, 2023, at 10:50 a.m. EST. Webcast available on atarabio.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.99%
Tags
Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to present at Stifel Healthcare Conference on November 14, 2023, discussing T-cell immunotherapy and EBV T-cell platform. Pascal Touchon, President and CEO, to participate in a fireside chat at 8:30 a.m. PST / 11:30 a.m. EST. Webcast available on atarabio.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.74%
Tags
Atara Biotherape
Nasdaq:ATRA
ATRA Rankings
ATRA Stock Data
36.15M
4.52M
21.98%
50.5%
12.2%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
THOUSAND OAKS